At this year's Thomas E. Starzl lecture, an expert in the field will discuss the most recent developments and controversies concerning living donor liver transplantation. The lecture will encompass topics like the current need for living organ donors, and the balance of donor and recipient risks with benefits for both parties in this life-saving procedure.
This engaging session will explore hot topics in the management of liver cancer, including talks on hepatobiliary neoplasia and liver transplant. The program's first segment will address advancements in research on the pathogenesis and surgical management of liver cancer, while the second half provides analysis of the newest advances in the systemic management of both iCCA and HCC.
Véronique Loustaud‐Ratti, Alicia Anneraud, Paul Carrier, Marilyne Debette‐Gratien, Anne De Muret, Mattias Tallegas, Hélène Barraud, Louise Barbier, Ephrem Salamé – 13 November 2020
Xuemei Gu, Rui Sun, Liang Chen, Shenghui Chu, Mark A. Doll, Xiaohong Li, Wenke Feng, Leah Siskind, Craig J. McClain, Zhongbin Deng – 13 November 2020
Mark R. Pedersen, Garrett Greenan, Sumant Arora, Arvind R. Murali, Marlyn J. Mayo – 13 November 2020 – After liver transplantation (LT), the role of ursodeoxycholic acid (UDCA) is not well characterized. We examine the effect of UDCA after LT in the prophylaxis of biliary complications (BCs) in all‐comers for LT and the prevention of recurrent primary biliary cholangitis (rPBC) in patients transplanted for PBC.
Krystal L. Karunungan, Yas Sanaiha, Roland A. Hernandez, Holly Wilhalme, Sarah Rudasill, Joseph Hadaya, Joseph DiNorcia, Peyman Benharash – 13 November 2020 – Although socioeconomic disparities persist both pre‐ and post‐transplantation, the impact of payer status has not been studied at the national level. We examined the association between public insurance coverage and waitlist outcomes among candidates listed for liver transplantation (LT) in the United States. All adults (age ≥18 years) listed for LT between 2002 and 2018 in the United Network for Organ Sharing database were included.
Michel Bazinet, Victor Pântea, Valentin Cebotarescu, Lilia Cojuhari, Pavlina Jimbei, Mark Anderson, Jeff Gersch, Vera Holzmayer, Carina Elsner, Adalbert Krawczyk, Mary C. Kuhns, Gavin Cloherty, Ulf Dittmer, Andrew Vaillant – 13 November 2020 – The nucleic acid polymer REP 2139 inhibits assembly/secretion of hepatitis B virus (HBV) subviral particles. Previously, REP 2139‐Ca and pegylated interferon (pegIFN) in HBV/hepatitis delta virus (HDV) coinfection achieved high rates of HDV RNA and hepatitis B surface antigen (HBsAg) loss/seroconversion in the REP 301 study (NCT02233075).
Laura J. Kitto, Neil C. Henderson – 13 November 2020 – The hepatic mesenchyme has been studied extensively in the context of liver fibrosis; however, much less is known regarding the role of mesenchymal cells during liver regeneration. As our knowledge of the cellular and molecular mechanisms driving hepatic regeneration deepens, the key role of the mesenchymal compartment during the regenerative response has been increasingly appreciated.
Zoe N. Memel, Ashwini Arvind, Oluwatoba Moninuola, Lisa Philpotts, Raymond T. Chung, Kathleen E. Corey, Tracey G. Simon – 13 November 2020 – Hepatocellular carcinoma (HCC) is the third‐leading cause of cancer‐related death worldwide, with a growing incidence and poor prognosis. While some recent studies suggest an inverse association between aspirin use and reduced HCC incidence, other data are conflicting. To date, the precise magnitude of risk reduction—and whether there are dose‐dependent and duration‐dependent associations—remains unclear.